$KNTK

ISQ Global Fund II GP LLC (Wahba Sadek, Bhandari Gautam) sold $3.7M of KNTK (indirect holdings)

ISQ Global Fund II GP LLC sold 68,005 indirectly-held shares of Kinetik Holdings Inc. (KNTK) at an average of $54.36 ($54.32–$55.07, $3.70M total) across 3 trades over 2026-08-18 to 2026-08-20. Filed jointly with I Squared Capital, LLC (10% owner), ISQ Holdings, LLC (10% owner), Wahba Sadek (10% owner) and Bhandari Gautam (10% owner).

Original reporting
SEC EDGAR · ISQ Global Fund II GP LLC, I Squared Capital, LLC, ISQ Holdings, LLC, Wahba Sadek, Bhandari Gautam
Published Aug 20, 2026, 10:59 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 11:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$KNTK
Bearish
medium confidence
Mentioned
$KNTK
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KNTKBearishLow
01

Why it matters

The disclosed sale may influence short‑term trading sentiment but is unlikely to drive long‑term price movement.

02

Market read

Primary insider sale provides new data for traders monitoring KNTK; limited broader market impact.

03

What to watch

The insider still retains a large stake (over 925k shares) and the sale was executed via multiple small trades, indicating possible liquidity management.

Relevance 6/10Novelty 5/10Timing: filed today (2026‑08‑20)

Background

Form 4 filings disclose insider transactions and are considered primary sources of material information.

Company-level read

Ticker impact

$KNTKBearishMedium confidence
Context

ISQ Global Fund II GP LLC sold $3.7M of KNTK shares (68,005 shares) via open‑market transactions on 2026‑08‑18 to 2026‑08‑20.

Expected impact

Possible short‑term dip of 1‑2% as the market digests the insider sell.

Evidence & confidence

While the transaction size is relatively small for the market, it is a primary Form 4 filing and the insider holds a 10% stake, making the sale noteworthy for traders.

Market effects

Minimal impact on the broader biotech sector; the sale is company‑specific.

No significant regional effect; limited to investors tracking KNTK.

Low global relevance.

Counterpoint

The sale could be a routine portfolio rebalancing rather than a negative signal, suggesting the stock may be undervalued.

Key entities

  • Kinetik Holdings Inc.

    US‑listed biotech firm (ticker KNTK).

  • ISQ Global Fund II GP LLC

    10% owner of KNTK reporting the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KNTKMed

Kinetik Q2 Earnings Call Highlights

Kinetik (NYSE:KNTK) Q2 earnings call said Waha pricing normalization and faster curtailment return, higher WTI and liquids assumptions, and system operating improvements supported a revised outlook. It raised 2026 capex to about $560M, expects Q3 Adjusted EBITDA $260M-$270M and Q4 $270M-$280M, and lifted 2026 volume growth to mid- to high-single digits.

$KNTKHighAI 9/10

Kinetik Holdings Inc. (KNTK): Results of Operations and Financial Condition

Kinetik Holdings Inc. (KNTK) filed an SEC Form 8-K — Results of Operations and Financial Condition. Kinetik Reports Record Second Quarter 2026 Results and Raises Full Year 2026 Guidance HOUSTON and MIDLAND, Texas, August 5, 2026 – Kinetik Holdings Inc. (NYSE: KNTK) (“ Kinetik ” or the “ Company ”) today reported record results for the quarter ended June 30, 2026 and increased i